Free Trial

Axsome Therapeutics (AXSM) News Today

Axsome Therapeutics logo
$103.98 -1.09 (-1.04%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$106.90 +2.92 (+2.81%)
As of 08:24 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AXSM Latest News

Axsome Therapeutics, Inc. stock logo
TFG Asset Management GP Ltd Makes New $3.49 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
TFG Asset Management GP Ltd purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 41,250 shares of the company's stock, val
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Bought by Nuveen Asset Management LLC
Nuveen Asset Management LLC raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 118.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 221,202 shares of the company's stock after buying an
Axsome Therapeutics, Inc. stock logo
ProShare Advisors LLC Raises Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
ProShare Advisors LLC raised its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 30.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,664 shares of the company's stock after acquiring an addit
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC Wainwright
HC Wainwright restated a "buy" rating and issued a $180.00 price target on shares of Axsome Therapeutics in a report on Thursday.
Axsome Therapeutics, Inc. stock logo
Captrust Financial Advisors Has $250,000 Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Captrust Financial Advisors reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 48.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,953 shares of the company's stock after s
Axsome Therapeutics, Inc. stock logo
Woodline Partners LP Acquires 109,872 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Woodline Partners LP lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 36.8% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 408,441 shares of the company's stock after purchasing an additional 109,872 shares during the period. Wood
Axsome Therapeutics, Inc. stock logo
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Makes New Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) have received a consensus rating of "Buy" from the fifteen research firms that are covering the stock, MarketBeat reports. Fourteen analysts have rated the stock with a buy rating and one has issued a strong buy rating on the co
Axsome Therapeutics, Inc. stock logo
TFG Asset Management GP Ltd Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
TFG Asset Management GP Ltd bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 41,250 shares of the company's stock, va
Axsome Therapeutics, Inc. stock logo
Man Group plc Acquires New Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Man Group plc acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 163,388 shares of the company's stock, valued at approximately $13,824,000. Man Group p
Axsome Therapeutics, Inc. stock logo
Deutsche Bank AG Purchases 32,789 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Deutsche Bank AG raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 37.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 120,547 shares of the company's stock after purchasing an additi
Axsome Therapeutics, Inc. stock logo
RTW Investments LP Cuts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
RTW Investments LP lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 3.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 4,051,365 shares of the company's stock after selling
Axsome Therapeutics, Inc. stock logo
Point72 Europe London LLP Grows Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Point72 Europe London LLP boosted its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 41,734 shares of the company's stock after purchasing an additional 7,164 shares du
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by Cantor Fitzgerald to Strong-Buy Rating
Cantor Fitzgerald raised Axsome Therapeutics to a "strong-buy" rating in a research report on Wednesday.
Axsome Therapeutics, Inc. stock logo
Comerica Bank Cuts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Comerica Bank trimmed its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 32.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,374 shares of the company's stock after selling 3,5
Axsome Therapeutics, Inc. stock logo
MPM Bioimpact LLC Invests $4.23 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
MPM Bioimpact LLC acquired a new stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 50,000 shares of the company's stock, valued at approximately $4,230,000.
Axsome Therapeutics, Inc. stock logo
Lazard Asset Management LLC Raises Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Lazard Asset Management LLC grew its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 525.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 537,669 shares of the company's stock aft
Axsome Therapeutics, Inc. stock logo
BNP Paribas Financial Markets Has $15.71 Million Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
BNP Paribas Financial Markets increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 1,251.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 185,661 shares of the comp
Axsome Therapeutics, Inc. stock logo
Northern Trust Corp Acquires 69,918 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Northern Trust Corp lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 21.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 402,500 shares of the company's stock after purchasing an additional 69,918 shares during the quarter. N
Axsome Therapeutics, Inc. stock logo
HC Wainwright Issues Pessimistic Forecast for AXSM Earnings
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Wednesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will ear
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Frontier Capital Management Co. LLC
Frontier Capital Management Co. LLC lessened its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 56.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 52,768 shares of the compa
3 Monster Stocks in the Making
Axsome Therapeutics, Inc. stock logo
Balyasny Asset Management L.P. Increases Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Balyasny Asset Management L.P. raised its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 171.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 181,213 shares of the company's stock after purch
Axsome Therapeutics, Inc. stock logo
Q2 EPS Forecast for Axsome Therapeutics Boosted by Analyst
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a report issued on Monday, May 5th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of ($1.21)
Axsome Therapeutics, Inc. stock logo
Q2 EPS Forecast for Axsome Therapeutics Lifted by Analyst
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Equities research analysts at William Blair increased their Q2 2025 earnings per share estimates for shares of Axsome Therapeutics in a research note issued on Monday, May 5th. William Blair analyst M. Minter now anticipates that the company
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Fairmount Funds Management LLC
Fairmount Funds Management LLC reduced its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 37.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,468,983 shares of the company's st
Axsome Therapeutics, Inc. stock logo
Cubist Systematic Strategies LLC Purchases New Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Cubist Systematic Strategies LLC bought a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 116,937 shares of the company's stock, valued at approximately $9,894,000.
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $180.00 at HC Wainwright
HC Wainwright reduced their target price on Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating for the company in a report on Wednesday.
Axsome Therapeutics, Inc. stock logo
William Blair Analysts Increase Earnings Estimates for AXSM
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Stock analysts at William Blair raised their FY2028 earnings per share estimates for shares of Axsome Therapeutics in a research note issued to investors on Monday, May 5th. William Blair analyst M. Minter now forecasts that the company will
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Purchased by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 12.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 31,228 shares of the company's stock after acquiring an additional 3,366 shares during the p
Axsome Therapeutics, Inc. stock logo
Robert W. Baird Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
Robert W. Baird increased their price objective on shares of Axsome Therapeutics from $160.00 to $162.00 and gave the stock an "outperform" rating in a research note on Tuesday.
Axsome Therapeutics, Inc. stock logo
Brevan Howard Capital Management LP Boosts Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Brevan Howard Capital Management LP increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 169.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 38,748 shares of the company
Axsome Therapeutics, Inc. stock logo
Schonfeld Strategic Advisors LLC Has $2.15 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Schonfeld Strategic Advisors LLC lessened its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 69.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,380 shares of the company's stock after selling 56,617 shares du
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.6% on Better-Than-Expected Earnings
Axsome Therapeutics (NASDAQ:AXSM) Shares Up 5.6% After Earnings Beat
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Issues Quarterly Earnings Results
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) issued its earnings results on Monday. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.23) by $0.43. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.
Axsome Therapeutics, Inc. stock logo
Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.43 EPS
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) announced its earnings results on Monday. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.23) by $0.43. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%.
Axsome Therapeutics, Inc. stock logo
Bridgefront Capital LLC Purchases Shares of 10,555 Axsome Therapeutics, Inc. (NASDAQ:AXSM)
Bridgefront Capital LLC acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 10,555 shares of the company's stock, valued at approximately $893,000. Several o
Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.

AXSM Media Mentions By Week

AXSM Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AXSM
News Sentiment

1.02

1.03

Average
Medical
News Sentiment

AXSM News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AXSM Articles
This Week

15

10

AXSM Articles
Average Week

Get Axsome Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:AXSM) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners